Yes, I know the mechanics of the licencing arrangement between Mesoblast and TiGenix.
What I can't understand is the business practice of MSB leaving revenue on the table by not selling product directly; rather than by a de facto agency arrangement.
PS. I'm unsure as to the relevance of Takeeda acquiring TiGenix a month after the licencing deal with MSB. Surely you aren't suggesting that Takeeda forked out over 500m euros for TiGenix because of its deal with MSB, are you?
MSB
Price at posting:
$1.55 Sentiment: None Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.